Relmacabtagene Autoleucel clinical trials
Relmacabtagene Autoleucel is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Ming Ju Biotechnology Co., Ltd (2). The most-studied condition is B-cell Non Hodgkin Lymphoma.
Patient leaflets for Relmacabtagene Autoleucel
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Relmacabtagene Autoleucel
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma
|
Phase 2 | Recruiting | Ruijin Hospital | China |
|
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
|
Observational | Not yet open | Shanghai Ming Ju Biotechnology Co., Ltd | China |
|
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841 · ClinicalTrials.gov ↗ · Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma
|
Phase 2 | Active, closed | Shanghai Ming Ju Biotechnology Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Relmacabtagene Autoleucel
8 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Shanghai Ming Ju Biotechnology Co., Ltd | 2 |
| Ruijin Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Relmacabtagene Autoleucel trials
How many clinical trials are testing Relmacabtagene Autoleucel?
3 current trials in our China register name Relmacabtagene Autoleucel as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Relmacabtagene Autoleucel trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Relmacabtagene Autoleucel clinical trials?
Shanghai Ming Ju Biotechnology Co., Ltd (2) and Ruijin Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Relmacabtagene Autoleucel works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Relmacabtagene Autoleucel works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Relmacabtagene Autoleucel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.